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Abstract:  The Malayan pit viper,  Calloselasma rhodostoma, produces  a potent venom 
toxin, rhodocytin (aggretin) which causes platelet aggregation. Rhodocytin is a ligand for 
the receptor CLEC-2 on the surface of platelets. The interaction of these two molecules 
initiates a signaling pathway which results in platelet activation and aggregation. We have 
previously solved the crystal structures of CLEC-2 and of rhodocytin, and have proposed 
models  by  which  tetrameric  rhodocytin  may  interact  with  either  two  monomers  of  
CLEC-2, or with one or two copies of dimeric CLEC-2. In the current study we use a range 
of approaches to analyze the molecular interfaces and dynamics involved in the models of 
the interaction of rhodocytin with either one or two copies of dimeric CLEC-2, and their 
implications for clustering of CLEC-2 on the platelet surface.  
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1. Introduction 
A range of snake toxins  have evolved to  influence blood  clotting and platelet aggregation [1]. 
Various C-type lectin-like proteins influence platelet aggregation through interactions with receptors 
on  the  surface  of  platelets;  a  number  of  these  venom  proteins  are  heterodimeric  [2,3].  Platelet 
activation  and  aggregation  can  be  triggered  by  various  well  defined  receptors  on  the  surface  of 
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platelets. Under typical physiological conditions, GPIb-V-IX and αIIbβ3 integrin interact with von 
Willebrand  factor  when  the  latter  has  become  attached  to  extracellular  collagen.  Collagen  itself 
interacts with the immunoglobulin superfamily receptor GPVI and the integrin α2β1 [4,5]. There is 
great biomedical interest in the discovery of novel platelet-activating receptors and in this respect the 
identification of the targets on platelets for snake venom proteins has been an important objective. 
The Malayan pit viper Calloselasma rhodostoma is a major cause of snakebite morbidity in large 
parts of Southeast Asia and effects on platelet function are key consequences of envenomation [6]. The 
pit viper produces a venom protein, rhodocytin (aggretin) which was purified and shown to cause 
powerful platelet activation and aggregation [7,8]. The molecular cloning and sequence analysis of 
rhodocytin demonstrated that the two subunits, designated alpha and beta, each have characteristics of 
the C-type lectin-like family [9]. Rhodocytin has been shown to be a ligand for CLEC-2, a recently 
identified receptor on the surface of platelets [10]. Binding of rhodocytin to CLEC-2 triggers a potent 
platelet signaling pathway [10,11]. CLEC-2 contains a single YXXL motif in its cytoplasmic tail. 
Rhodocytin  binding  leads  to  tyrosine  phosphorylation  in  this  cytoplasmic  tail  of  CLEC-2,  which 
promotes the binding of spleen tyrosine kinase (Syk), subsequent activation of PLCγ2 and platelet 
activation  and  aggregation  [10].  CLEC-2  is  encoded  in  a  genomic  cluster  with  related  C-type  
lectin-like molecules, some of which have immunological roles, as exemplified by NKG2D [12–17]. 
CLEC-2 was first identified as a receptor on platelets for rhodocytin and may also play a role in 
lymphatic development [10,18]. We and others have shown that podoplanin is an endogenous ligand 
for CLEC-2 [16,19]. Podoplanin is expressed on the luminal aspect of lymphatic endothelial cells and 
in a range of tissues including kidney, heart, lung and many tumours [20]. The biological importance 
of CLEC-2 and podoplanin is indicated by observations that genetic knockouts of either molecule are 
lethal during embryonic development [21–28]. 
The  mechanism  whereby  rhodocytin  triggers  platelet  aggregation  is  of  great  interest  because  a 
detailed knowledge of CLEC-2-mediated platelet activation could be of value in understanding and 
preventing platelet aggregation in thrombotic coronary and cerebral vascular disease, which are major 
causes  of  disability  and  death  worldwide.  Furthermore,  there  is  a  strong  need  to  understand  the 
rhodocytin-CLEC-2  interaction  in  its  own  right  as  snake  envenomation  affects  over  2.5  million 
humans per year, causing more than 100,000 deaths [29]. We have solved the structure of the C-type 
lectin-like  domain  of  CLEC-2  and  have  used  mutagenesis  to  characterise  the  interaction  with 
rhodocytin  [30,31].  The  binding  affinity  of  CLEC-2  with  rhodocytin  and  podoplanin  has  been 
measured using surface plasmon resonance (Biacore technology) [16,30,32]. We found the affinity of 
the  interaction  of  rhodocytin  with  monomeric  CLEC-2  to  be  1.01  ±  0.20  μM,  as  compared  with  
24.5 ±  3.7 μM and 4.1 ±  0.2 μM for the interactions of podoplanin with monomeric and dimeric 
CLEC-2 respectively [16,30,32]. 
To further explore the association between CLEC-2 and rhodocytin, we have also solved the crystal 
structure of rhodocytin, and discovered that it assembles as a non-disulfide linked (αβ)2 tetramer [33]. 
Rhodocytin  is  the  first  snake  venom  or  other  C-type  lectin-like  protein  reported  to  adopt  this 
configuration. We proposed that the rhodocytin tetramer might induce clustering of CLEC-2 molecules 
on the platelet surface and that this could play a key role in triggering signaling to platelet activation. 
We have previously generated three models of the rhodocytin-CLEC-2 interaction, whereby tetrameric 
rhodocytin may promote clustering of CLEC-2 by interacting with two copies of monomeric CLEC-2, Toxins 2011, 3                                       
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one copy of dimeric CLEC-2, or two copies of dimeric CLEC-2. We have since used a range of 
cellular, biochemical and biophysical techniques to demonstrate that CLEC-2 exists as a non-disulfide-
linked  homodimer  [32].  Although  Syk  generally  interacts  with  two  YXXL  motifs  on  a  single 
polypeptide chain, there is evidence to indicate that it can interact with two YXXL motifs, each from a 
different CLEC-2 chain, consistent with CLEC-2 functioning in a dimeric manner in its interaction 
with Syk [34]. These observations preclude the first of our original models of the rhodocytin-CLEC-2 
interaction, wherein two copies of monomeric CLEC-2 bind to tetrameric rhodocytin. In the current 
study, we analyse and discuss the interactions involved in the two other models of the interaction, 
where rhodocytin may bind either one or two copies of dimeric CLEC-2, and discuss the implications 
for clustering of CLEC-2 on the platelet surface. 
2. Materials and Methods 
2.1. Protein Interfaces, Surfaces and Assemblies 
Algorithms implemented by PISA (Protein interfaces, surfaces and assemblies version 1.2) were 
used to explore the macromolecular protein interfaces of the model complexes of rhodocytin plus 
either one, or two copies of model dimeric CLEC-2 [35]. These models were generated as previously 
reported [33]. These calculations included the structural and chemical properties of macromolecular 
surfaces and interfaces, the accessible/buried surface area, the free energy of dissociation, and the 
presence or absence of salt bridges  and disulfide bonds. The protein database archive (PDB) was 
searched for particular interfaces formed by structural homologs, and the PISA database was explored 
to compare results for multimeric state, symmetry number, space group, accessible/buried surface area, 
free energy of dissociation, presence/absence of salt bridges and disulfide bonds, homomeric type, and 
ligands.  Structures,  interfaces  and  assemblies  were  visualised  for  analysis  using  Rastop  and  Jmol  
(an open-source Java viewer for chemical structures in 3D. http://www.jmol.org/). 
2.2. Molecular Dynamics 
The potential modes of motion of the different models of the rhodocytin-CLEC-2 complex were 
examined and analysed using the Dynamite package [36]. From the input three dimensional structure, 
an ensemble of structures was generated, and subsequently analysed to predict which elements move 
together and the relevant vectors of these motions. The ensemble was generated using Concoord, and 
the analysis was performed using Gromacs. In essence, Concoord is used to identify all interatomic 
interactions in the structure which is input [37]. The likely strength of these interactions is analysed 
and so the potential freedom of the interacting species is modeled to within appropriate bounds. Following 
this, new variant structures are established that fulfill the limitations of these modeled bounds. These 
dynamic analyses were represented graphically using Visual Molecular Dynamics (VMD) [38]. Toxins 2011, 3                                       
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3. Results and Discussion 
3.1. The Interaction Surfaces of the Rhodocytin-CLEC-2 Interaction 
There are two alpha and two beta subunits of rhodocytin per tetrameric unit. The most basic model 
of the interaction of rhodocytin with CLEC-2 is that in which one molecule of dimeric CLEC-2 is 
complexed with one molecule of rhodocytin, the rhodocytin being in the form of the non-disulfide 
linked  (αβ)2  tetramer  that  was  identified  by  crystallography  [33].  In  this  complex,  there  are  two 
hydrogen bonds and one salt bridge involved in the interaction between dimeric CLEC-2 and one beta 
subunit of rhodocytin (Table 1). However, in this model, the other beta subunit of the tetramer does not 
bind to the CLEC-2 dimer (Table 1). In addition to the interactions with the beta subunit of rhodocytin, 
dimeric CLEC-2 interacts with one alpha subunit of rhodocytin through five hydrogen bonds and three 
salt bridges (Table 1). In contrast to the beta subunits, where only one interacts with CLEC-2, this 
second alpha subunit does interact with the CLEC-2 dimer in this model, but does not form any ionic 
bonds with it (Table 1). It is likely that this interaction with the second alpha subunit is mediated by 
van der Waals forces. 
The more complex model of the rhodocytin-CLEC-2 interaction involves two copies of dimeric 
CLEC-2 bound to one molecule of the non-disulfide linked (αβ)2 tetrameric form of rhodocytin. It is 
important  to  note  that  this  model  is  distinct  from  that  described  above,  and  has  been  generated 
independently in a way that has not been influenced by the first model. In this complex, four hydrogen 
bonds and one salt bridge are involved in the interaction between each molecule of dimeric CLEC-2 
and each rhodocytin beta subunit (Table 2). In addition, the interaction between each alpha subunit of 
rhodocytin and each molecule of dimeric CLEC-2 involves a further two hydrogen bonds and one salt 
bridge  (Table  2).  Clearly,  this  model  in  which  two  CLEC-2  dimers  associate  with  tetrameric 
rhodocytin involves more numerous and favourable ionic interactions and hydrogen bonds (a total of 
sixteen, as opposed to eleven interactions per tetramer of rhodocytin) in addition to van der Waals 
contacts  and  would  therefore  be  a  more  likely  model  (Figure  1).  Interestingly,  residue  K150  of  
CLEC-2, which we identified as being important for its interaction with rhodocytin using mutagenesis 
and surface plasmon resonance, is also involved in the interface in this model of the complex [30]. 
There are 246 bound water molecules present in the crystal structure of monomeric CLEC-2 and  
45 water molecules present in the crystal structure of rhodocytin. Therefore, upon dimerization of  
CLEC-2  and  complexing  of  this  dimeric  CLEC-2  with  tetrameric  rhodocytin,  there  will  be 
considerable liberation of the water molecules which solvate the unbound molecules. In our model 
where one copy of dimeric CLEC-2 binds tetrameric rhodocytin, the alpha subunits and the one beta 
subunit  involved in  the complex experience  gains  in  the free energy of solvation of 1.5, 2.5  and  
0.2 kcal/mol respectively (total 4.2 kcal/mol). However, in our more complex model in which two 
CLEC-2 dimers bind to one tetramer of rhodocytin, the solvation energy gains for each CLEC-2 dimer 
interaction are 0.2 and 0.6 kcal/mol for the alpha subunits, and 2.2 and 0.7 kcal for the two beta 
subunits  (total  7.4  kcal/mol).  There  is,  therefore,  a  more  appreciable  gain  in  the  free  energy  of 
solvation  upon  formation  of  the  complex  of  two  CLEC-2  dimers  rather  than  one  with  tetrameric 
rhodocytin, which again indicates that this is a more plausible model. Toxins 2011, 3                                       
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Table 1. Contact information and interfacing residues involved in the model interaction of one copy of dimeric CLEC-2 with tetrameric 
rhodocytin. Key: H = residues making hydrogen bonds, S = residues making a salt bridge, ASA = accessible surface area (Å² ), BSA = buried 
surface area (Å²), ΔiG = solvation energy effect (kcal/mol), |||| = buried area percentage, one bar per 10%. 
   Rhodocytin alpha chain #1  CLEC-2    Rhodocytin alpha chain #1  Ionic bond  ASA  BSA  ΔiG    CLEC-2  Ionic bond  ASA  BSA  ΔiG 
Number of atoms                GLN 23       121.22    3.01 |    −0.01     ASP 188       138.86    6.93 |    −0.03  
interface    17   (1.5%)    18   (0.9%)     THR 25        22.63    0.37 |    −0.00     LYS 190       135.33    86.75 |||||||    −0.38  
surface    715   (63.8%)    1129   (54.1%)     GLU 28       75.89    9.81 ||    −0.17     ASN 192       110.81    36.12 ||||    −0.02  
total    1121   (100.0%)    2085   (100.0%)     ASP 100       142.06    7.22 |    −0.12     PHE 207       59.76    31.74 ||||||    0.51  
 Number of residues                 HIS 102       113.98    18.44 ||    −0.05     ASN 210       66.39    2.72 |    0.00  
interface    8   (6.0%)    5   (2.1%)     GLU 124       74.46    21.29 |||    0.20                   
surface    123   (92.5%)    222   (91.7%)      GLN 125       78.37    23.20 |||    −0.00                   
total    133   (100.0%)    242   (100.0%)      MET 126       86.41    66.86 ||||||||    1.61                   
 Solvent-accessible area, Å
2                                      
interface    150.2   (1.8%)    164.3   (1.3%)                          
total    8404.1   (100.0%)    12294.5   (100.0%)                          
 Solvation energy, kcal/mol                                     
isolated structure    −94.6   (100.0%)    −222.4   (100.0%)                          
gain at complexation    −1.5   (1.5%)    −0.1   (0.0%)                          
average gain    −0.6   (0.6%)    −0.1   (0.0%)                          
P-value    0.229       0.543                             
   Rhodocytin alpha chain #2  CLEC-2    Rhodocytin alpha chain #2  Ionic bond  ASA  BSA  ΔiG    CLEC-2  Ionic bond  ASA  BSA  ΔiG 
Number of atoms                GLN 23  H    120.27    74.93 |||||||    −0.33     ASN 120       97.19    3.68 |    0.00  
interface    52   (4.6%)    68   (3.3%)     GLU 28       81.78    1.71 |    −0.02     LYS 150       76.82    4.77 |    0.03  
surface    713   (63.6%)    1129   (54.1%)     ASP 66       125.72    28.70 |||    0.14     HIS 154  HS    42.91    12.38 |||    −0.24  
total    1121   (100.0%)    2085   (100.0%)     GLU 67       18.44    1.15 |    0.02     LEU 155       46.25    4.86 ||    0.08  
 Number of residues                 ASP 68  HS    85.58    75.58 |||||||||    −0.77     ILE 156       42.53    22.40 ||||||    0.02  
interface    15   (11.3%)    22   (9.1%)     TYR 69       37.03    3.53 |    0.05     GLU 187       57.90    1.47 |    −0.02  
surface    123   (92.5%)    222   (91.7%)     ASP 100  HS    142.47    47.16 ||||    −0.02     TYR 197       38.02    10.89 |||    −0.11  
total    133   (100.0%)    242   (100.0%)     HIS 102       113.24    7.72 |    −0.29     HIS 199       51.26    47.31 ||||||||||    −0.90  
 Solvent-accessible area, Å
2                 LYS 111  H    91.53    63.63 |||||||    −0.03     ASN 200       79.07    56.83 ||||||||    −0.09  
interface    587.3   (7.0%)    537.5   (4.4%)     LEU 112       155.55    127.31 |||||||||    1.55     LYS 202  H    95.17    47.42 |||||    −0.42  
total    8416.9   (100.0%)    12294.5   (100.0%)     GLY 114       47.05    5.54 ||    0.06     HIS 204       43.12    29.08 |||||||    0.07  
 Solvation energy, kcal/mol                GLU 124       72.61    2.09 |    −0.02     GLU 209       125.40    0.61 |    −0.01  
isolated structure    −94.8   (100.0%)    −222.4   (100.0%)     GLN 125       72.41    55.90 ||||||||    0.02     ASN 210       66.39    8.19 ||    0.01  
gain at complexation    −2.5   (2.6%)    2.8   (−1.3%)     MET 126       94.24    79.53 |||||||||    1.92     LYS 211  HS    122.09    33.70 |||    −0.14  
average gain    −1.7   (1.8%)    −0.3   (0.2%)     HIS 127       19.00    12.81 |||||||    0.20     HIS 212       32.27    7.81 |||    0.13  
P-value    0.373       0.895                         ARG 118  HS    100.93    45.82 |||||    −0.76  
                             ASN 120        102.89    66.75 |||||||    0.09  
                             LEU 155       42.73    22.76 ||||||    0.36  
                             ILE 156       44.58    18.67 |||||    0.05  
                             LYS 211       116.36    11.88 ||    −0.04  
                             HIS 212       33.89    19.92 ||||||    −0.78  
                             TYR 213  H    60.85    60.26 ||||||||||    −0.15  
   Rhodocytin beta chain #1  CLEC-2    Rhodocytin beta chain  Ionic bond  ASA  BSA  ΔiG    CLEC-2  Ionic bond  ASA  BSA  ΔiG 
Number of atoms                ASN 22       69.56    20.99 ||||    −0.00     ASN 120       97.19    23.61 |||    0.02  
interface    18   (1.7%)    12   (0.6%)     ARG 100       96.44    12.38 ||    −0.16     LYS 211  HS    122.09    27.30 |||    −1.01  
surface    638   (61.6%)    1129   (54.1%)     GLU 105  HS    81.89    22.63 |||    −0.07     GLU 187       54.63    19.30 ||||    −0.30  
total    1035   (100.0%)    2085   (100.0%)     LEU 107       47.78    10.71 |||    0.17     ASP 188       135.67    6.75 |    −0.08  
 Number of residues                 ASP 110       76.19    0.24 |    −0.00     LYS 202  H    90.50    65.54 ||||||||    −0.48  
interface    8   (6.5%)    6   (2.5%)     SER 112  H    79.62    35.64 |||||    −0.17     HIS 204       48.24    11.72 |||    0.19  
surface    112   (91.1%)    222   (91.7%)     SER 113       39.33    5.85 ||    0.09                   
total    123   (100.0%)    242   (100.0%)     THR 114       83.92    22.18 |||    0.35                   
 Solvent-accessible area, Å
2                                      
interface    130.6   (1.6%)    154.2   (1.3%)                          
total    7933.1   (100.0%)    12294.5   (100.0%)                          
 Solvation energy, kcal/mol                                     
isolated structure    −107.9   (100.0%)    −222.4   (100.0%)                          
gain at complexation    −0.2   (0.2%)    1.7   (−0.7%)                          
average gain    −0.5   (0.5%)    −0.1   (0.0%)                          
P-value    0.609       0.935                             Toxins 2011, 3                                       
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Table 2. Contact information and interfacing residues involved in the model interaction of two copies of dimeric CLEC-2 with tetrameric 
rhodocytin. Key: H = residues making hydrogen bonds, S = residues making a salt bridge, ASA = accessible surface area (Å² ), BSA = buried 
surface area (Å²), ΔiG = solvation energy effect (kcal/mol), |||| = buried area percentage, one bar per 10 %. 
   Rhodocytin alpha chain #1  CLEC-2    Rhodocytin alpha chain #1  Ionic bond  ASA  BSA  ΔiG    CLEC-2  Ionic bond  ASA  BSA  ΔiG 
Number of atoms                GLN 23       108.13    1.22 |    −0.02     ARG 143  HS    161.22    52.59 ||||    −0.74  
interface    19   (1.8%)    14   (0.7%)     GLU 67       14.14    0.49 |    −0.01     ASN 144       82.06    1.75 |    −0.02  
surface    698   (64.7%)    1091   (53.8%)     ASP 68  HS    81.41    35.61 |||||    −0.14     GLU 147       55.82    16.53 |||    −0.14  
total    1079   (100.0%)    2029   (100.0%)     TYR 69       36.42    7.12 ||    0.11     LYS 150       79.33    0.26 |    −0.01  
 Number of residues                 ASP 100       141.21    0.50 |    0.01     GLU 184       139.38    1.23 |    −0.01  
interface    11   (8.3%)    8   (3.3%)     LEU 112        147.96    15.33 ||    0.06     ASP 188       139.39    0.49 |    −0.01  
surface    123   (93.2%)    219   (90.9%)     THR 113       45.14    4.02 |    0.04     LYS 202       96.42    2.31 |    0.03  
total    132   (100.0%)    241   (100.0%)     TYR 121        35.14    2.70 |    −0.03     HIS 119       80.14    20.51 |||    0.23  
 Solvent-accessible area, Å
2                 TYR 122       69.39    2.21 |    −0.03                   
interface    86.1   (1.1%)    95.7   (0.8%)     GLN 125       64.01    1.17 |    −0.01                   
total    8163.2   (100.0%)    11998.6   (100.0%)     HIS 127       18.53    15.77 |||||||||    0.25                   
 Solvation energy, kcal/mol                                     
isolated structure    −102.9   (100.0%)    −240.7   (100.0%)                          
gain at complexation    −0.2   (0.2%)    0.7   (−0.3%)                          
average gain    −0.5   (0.4%)    0.0   (−0.0%)                          
P-value    0.590       0.737                             
   Rhodocytin alpha chain #2  CLEC-2    Rhodocytin alpha chain #2  Ionic bond  ASA  BSA  ΔiG    CLEC-2  Ionic bond  ASA  BSA  ΔiG 
Number of atoms                ASP 66  HS    130.36    79.17 |||||||    −0.03     ASN 120       78.74    8.01 ||    −0.09  
interface    51   (4.7%)    53   (2.6%)     ASP 68       81.94    71.50 |||||||||    −0.55     HIS 154       47.02    20.87 |||||    −0.20  
surface    699   (64.8%)    1085   (53.5%)     TYR 69       36.31    27.26 ||||||||    −0.04     LEU 155       35.70    29.71 |||||||||    0.48  
total    1079   (100.0%)    2029   (100.0%)     LYS 104       93.33    36.30 ||||    −1.07     ILE 156       53.72    53.60 ||||||||||    0.73  
 Number of residues                  GLU 110       23.39    6.91 |||    −0.06     GLU 187       56.68    10.36 ||    −0.12  
interface    14   (10.6%)    19   (7.9%)     LYS 111       93.46    64.69 |||||||    0.62     TYR 197       32.06    19.76 |||||||    −0.19  
surface    123   (93.2%)    220   (91.3%)     LEU 112       147.63    143.96 ||||||||||    1.57     HIS 199       50.16    48.10 ||||||||||    0.23  
total    132   (100.0%)    241   (100.0%)     THR 113       44.93    9.95 |||    0.07     ASN 200       79.01    17.04 |||    −0.12  
 Solvent-accessible area, Å
2                 GLY 114       46.88    2.48 |    −0.03     LYS 202  HS    98.88    29.20 |||    −0.57  
interface    562.3   (6.9%)    459.1   (3.8%)     LYS 117       141.41    26.11 ||    0.42     HIS 204       50.56    38.80 ||||||||    0.13  
total    8165.3   (100.0%)    12027.2   (100.0%)     TYR 121       35.30    25.21 ||||||||    −0.13     PHE 207       75.23    17.03 |||    0.27  
 Solvation energy, kcal/mol                TYR 122       68.95    35.37 ||||||    0.07     GLU 209       126.27    3.80 |    −0.04  
isolated structure    −103.6   (100.0%)    −240.8   (100.0%)     GLN 125  H    63.99    30.94 |||||    −0.33     ASN 210  H    58.58    45.69 ||||||||    −0.24  
gain at complexation    −0.6   (0.6%)    −0.5   (0.2%)     MET 126       101.87    2.47 |    0.10     LYS 211       115.90    44.00 ||||    −0.06  
average gain    −1.2   (1.2%)    0.2   (−0.1%)                      HIS 212       35.13    27.56 ||||||||    0.15  
P-value    0.638       0.406                         TYR 213       66.22    13.26 |||    0.21  
                             HIS 154       29.40    6.68 |||    −0.08  
                             HIS 199       52.25    16.26 ||||    0.15  
                             ASN 200       73.94    9.33 ||    −0.16  
   Rhodocytin beta chain #1  CLEC-2    Rhodocytin beta chain #1  Ionic bond  ASA  BSA  ΔiG    CLEC-2  Ionic bond  ASA  BSA  ΔiG 
Number of atoms                PRO 20       80.18    7.37 |    0.12     ARG 118       61.27    6.80 ||    −0.01  
interface    44   (4.4%)    45   (2.2%)     LEU 63       30.42    8.55 |||    0.14     HIS 119       78.21    35.49 |||||    −0.68  
surface    626   (62.2%)    1085   (53.5%)     GLN 91       119.63    31.40 |||    −0.47     ASN 120  H    78.74    50.66 |||||||    −0.21  
total    1006   (100.0%)    2029   (100.0%)     GLU 92       158.11    54.64 ||||    −0.10     LEU 121       32.06    29.72 ||||||||||    0.48  
 Number of residues                 GLN 93       105.23    12.72 ||    0.20     THR 122       29.65    12.79 |||||    0.20  
interface    15   (12.3%)    16   (6.6%)     SER 94       30.87    0.24 |    −0.00     GLU 124       105.69    3.56 |    0.06  
surface    111   (91.0%)    220   (91.3%)     GLU 95   S    50.04    24.82 |||||    −0.19     GLU 125       90.53    64.70 ||||||||    −0.51  
total    122   (100.0%)    241   (100.0%)     ARG 100       98.07    3.35 |    −0.12     GLN 128        94.77    6.26 |    0.10  
 Solvent-accessible area, Å
2                 ASN 108  H    74.11    14.85 |||    −0.22     TYR 129       54.87    16.90 ||||    0.27  
interface    390.7   (5.0%)    411.1   (3.4%)     MET 109       53.08    44.57 |||||||||    1.42     ASP 132       99.68    21.00 |||    −0.17  
total    7813.8   (100.0%)    12027.2   (100.0%)     ASP 110  H    75.54    64.97 |||||||||    0.15     LEU 155       35.70    5.35 ||    0.09  
 Solvation energy, kcal/mol               SER 112       83.61    44.24 ||||||    −0.13     LYS 211  HS    115.90    71.91 |||||||    −1.17  
isolated structure    −111.3   (100.0%)    −240.8   (100.0%)     SER 113       37.64    35.97 ||||||||||    0.58     TYR 213       66.22    33.75 ||||||    −0.29  
gain at complexation    −2.2   (1.9%)    1.8   (−0.7%)     THR 114       82.96    38.52 |||||    0.60     LYS 150       75.88    2.85 |    0.05  
average gain    −0.8   (0.8%)    0.1   (−0.1%)     CYS 115       10.14    4.47 |||||    0.18     HIS 154       29.40    1.51 |    0.02  
P-value    0.290       0.799                         ASN 200       73.94    47.86 |||||||    0.02  Toxins 2011, 3                                       
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Figure 1. Representation of an interface between CLEC-2 (white) and a beta subunit (pink) 
of the rhodocytin tetramer. Sidechains of interacting residues (N120 and K211 on CLEC-2, 
and E95 and D110 on the beta subunit of rhodocytin) are represented as balls and sticks. 
Predicted hydrogen bonds are represented by broken dotted blue lines. 
 
3.2. Dynamic Flexibility of the Rhodocytin-CLEC-2 Complexes 
Molecular dynamics analyses were undertaken to investigate the potential flexibility of the two 
possible rhodocytin-CLEC-2 interaction models (Figures 2, 3). With only a single dimer of CLEC-2 
interacting with tetrameric rhodocytin, the predicted motions are dominated by the alpha and beta 
subunits of rhodocytin and the motions of CLEC-2 appear to play a relatively minor part in the overall 
flexibility of the complex (Figure 2). Interestingly, in the model with two copies of dimeric CLEC-2 
bound to rhodocytin, a much greater contribution is made by the CLEC-2 dimers, and the beta subunits 
of  rhodocytin,  to  the  global  flexibility  of  the  complex  (Figure  3).  In  the  molecular  dynamics 
simulations  for  this  model,  the  CLEC-2  dimers  appear  to  wrap  around  the  grooves  presented  on 
rhodocytin, and the beta subunits move in a complementary fashion so as to maximise the exposure 
and accessibility of the two binding grooves to CLEC-2 (Figure 3). Thus, in this interaction mode with 
two CLEC-2 molecules, the alpha subunits of rhodocytin make a relatively more minor contribution to 
the possible dynamic motions of the complex (Figure 3). Toxins 2011, 3                                       
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Figure 2. Dynamic analyses of a model of the interaction of dimeric CLEC-2 (white) with 
tetrameric  rhodocytin.  The  rhodocytin  α-  and  β-chains  are  coloured  yellow  and  pink, 
respectively.  The  porcupine  plots  represent  the  principal  mode  of  conformational 
variability of the Cα atoms calculated from a CONCOORD ensemble using the model of 
the  rhodocytin-CLEC-2  interaction  based  on  the  crystal  structure  of  rhodocytin,  and  a 
model of the dimeric structure of CLEC-2. Blue cones  represent  the direction of each 
motion; the length of the cone is proportional to the amplitude of the motion. The top 
image represents a 90°  counter-clockwise rotation of the central image about the X-axis. 
The bottom image represents a 90°  clockwise rotation of the top image about the Y-axis. 
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Figure 3. Dynamic analyses of a model of the interaction of two copies of dimeric CLEC-2 
(white) with tetrameric rhodocytin. The rhodocytin α- and β-chains are coloured yellow 
and pink, respectively. The porcupine plots represent the principal mode of conformational 
variability of the Cα atoms calculated from a CONCOORD ensemble using the model of 
the  rhodocytin-CLEC-2  interaction  based  on  the  crystal  structure  of  rhodocytin,  and  a 
model of the dimeric structure of CLEC-2. Blue cones  represent  the direction of each 
motion; the length of the cone is proportional to the amplitude of the motion. The top 
image represents a 90°  counter-clockwise rotation of the central image about the X-axis. 
The bottom image represents a 90°  clockwise rotation of the top image about the Y-axis. 
 
4. Conclusions 
We have previously solved the crystal structures of both rhodocytin and CLEC-2, but there is no 
crystallographic structure of the rhodocytin-CLEC-2 complex. Using three dimensional structures of Toxins 2011, 3                                       
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both rhodocytin and CLEC-2, we have generated models of the likely modes of interaction of the 
venom protein and its receptor on platelets and have investigated and analysed the computational 
models of the interaction which we have generated [30,32,33]. Using a set of analytical algorithms and 
approaches, we have assessed the properties of the interfacing surfaces and the contribution made to 
the  interaction  by  specific  intermolecular  contacts,  including  salt  bridges  and  hydrogen  bonds.  In 
addition to this, we have evaluated the potential flexibility of these model complexes. The model 
wherein two molecules of CLEC-2 associate with tetrameric rhodocytin provides a more plausible 
model in terms of the composite effects related to the number of interfacing residues, the nature of 
their interactions and the predicted solvation energy effects. Further, it is of potential significance that 
the predicted dynamic motions of this complex are suggestive of a mechanism whereby this interaction 
might  cluster  the  receptors  on  the  platelet  surface,  which  could  have  implications  for  signaling. 
Overall, the work presented indicates that a plausible mode of binding is that of one non-disulfide 
linked (αβ)2 tetramer of rhodocytin with two dimers of CLEC-2. This analysis will be of value in the 
development  of  further  studies  to  characterise  the  interaction  further  with  a  view  to  developing 
therapeutic approaches to disrupt the rhodocytin-CLEC-2 interaction on the platelet surface. 
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